Over the past six months, Vishay Intertechnology’s shares (currently trading at $17.15) have posted a disappointing 7.2% loss while the S&P 500 was down 1.4%. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.
Over the last six months, Light & Wonder shares have sunk to $104.34, producing a disappointing 7.4% loss - worse than the S&P 500’s 1.4% drop. This might have investors contemplating their next move.
What a time it’s been for VSE Corporation. In the past six months alone, the company’s stock price has increased by a massive 44%, reaching $120 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.
Looking back on it services & other tech stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Amdocs (NASDAQ:DOX) and its peers.
Looking back on industrial & environmental services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Cintas (NASDAQ:CTAS) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at UFP Industries (NASDAQ:UFPI) and the best and worst performers in the building materials industry.
What a brutal six months it’s been for Desktop Metal. The stock has dropped 46.3% and now trades at $2.42, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers.